Double-blind Randomized Clinical Trial, Placebo-controlled to Assess the Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19: E-SPERANZA COVID-19 PROJECT

Cordero et al., NCT04695704, E-SPERANZA, NCT04695704, Aug 2023

Montelukast for COVID-19

32nd treatment shown to reduce risk in November 2021, now with p = 0.0041 from 9 studies.

Lower risk for hospitalization and cases.

No treatment is 100% effective.
Protocols combine treatments.

c19early.org

Meta-analysis

Estimated 284 patient montelukast late treatment RCT with results not reported over 3 years after estimated completion.

2 montelukast RCTs have results missing long after expected1,2
The trials report an estimated total of 664 patients.

Important missing comments or errors? Let us know.

1. Cordero et al., Double-blind Randomized Clinical Trial, Placebo-controlled to Assess the Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19: E-SPERANZA COVID-19 PROJECT, NCT04695704, clinicaltrials.gov/study/NCT04695704clinicaltrials.gov.

2. Durdagi et al., A National, Multi-Center, Open-Label, Three-Arm, Phase II Study to Investigate the Effect of Montelukast Between Emergency Room Visits and Hospitalizations in COVID-19 Pneumonia in Comparison With Standard Treatment, NCT04718285, clinicaltrials.gov/study/NCT04718285clinicaltrials.gov.

Cordero et al., 31 Aug 2023, Double Blind Randomized Controlled Trial, placebo-controlled, Spain, trial NCT04695704 (history) (E-SPERANZA). Contact: franmcor@hotmail.com, rmorros@idiapjgol.org.

Late treatment
is less effective